NK

Naru Konda Reddy

Director Director DIN 08748574
DIN 08748574 First appointment May 2020 Primary industry Healthcare
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since May 2020
Shareholding value β€’β€’β€’β€’ Premium profile

About Naru Konda Reddy

Data last updated:

Naru Konda Reddy was a Director at Swanridz Pharma Private Limited (2020) and Director at Prameela Laboratories Private Limited (2020–2022). The companies operate in Healthcare and Information Technology.

DIN 08748574
Primary Designation Director
Industry Healthcare
First Appointment 28 May 2020

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Swanridz Pharma Private Limited U24299AP2020PTC114613
Director28 May 20202020₹5.9 Lakh (FY 2025)Active
Director17 Jun 20202020₹13 Lakh (FY 2023)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Swanridz Pharma Private Limited
Prameela Laboratories Private Limited
Premium access

Shareholding and investment profile for Naru Konda Reddy

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Naru Konda Reddy

Naru Konda Reddy was first appointed on 28 May 2020 as Director at Swanridz Pharma Private Limited.

Naru Konda Reddy held 2 earlier board appointments: Swanridz Pharma Private Limited (Director, 28 May 2020 to 22 Jun 2020); Prameela Laboratories Private Limited (Director, 17 Jun 2020 to 16 Feb 2022).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available